Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| SP4555 | Other Grant/Funding Number | Action Medical Research |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Learning disability affects 3% of the population. Severe types of learning disability are more likely to have an underlying genetic cause but diagnosis is difficult because many different genetic abnormalities may be involved. Obtaining a diagnosis is important so that patients can be managed appropriately and their families can be given accurate information.
We aim to use new types of genetic testing which will make it possible to screen for several different genetic abnormalities which cause learning disability at the same time, so improving the accuracy and speed of diagnosis in the group of patients with severe learning disability. We will focus particularly on patients where seizures and behavioural problems are also present.This will enable more patients to be diagnosed accurately, reduce the number of hospital appointments needed and ultimately be more cost- effective.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Microarray / NGS test |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Genetic abnormality identified by microarray or Next Generation Sequencing | Abnormalities identified upon results of testing, the normal timeframe for this is up to 6 months after collecting blood sample. | up to 6 months following consent |
| Measure | Description | Time Frame |
|---|---|---|
| Cost effectiveness vs normal care | This analysis will be performed for all participants following close of recruitment & follow up, and will be completed by the time the study ends. | By the end of the study (December 2014) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
We will approach a cohort of patients with severe LD/seizures/behaviour problems who have presented to us in our genetic clinic for diagnosis over the past few years, but where the cause of their problems remains unknown. This will be our study population. In virtually all cases we will have performed routine diagnostic testing and will have stored DNA.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jill Clayton Smith, MB ChB FRCP MD | CMFT | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Manchester University Hospitals NHS Foundation Trust | Manchester | M13 9WL | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D007859 | Learning Disabilities |
| ID | Term |
|---|---|
| D003147 | Communication Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
DNA extracted from whole blood, saliva or skin biopsy
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |